Bronchogen

Overview

Bronchogen is a short tetrapeptide composed of alanine, glutamic acid, aspartic acid, and leucine (Ala-Glu-Asp-Leu, AEDL). It was developed within the Russian peptide bioregulator research program by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology.

Research Background

Bronchogen has been studied in research on respiratory tissue biology, bronchial epithelial cell function, and age-related changes in lung tissue. It is part of the broader category of tissue-specific bioregulators that includes Pinealon, Vilon, Cardiogen, and others.

Storage & Handling

Store lyophilized peptide at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within recommended timeframes. Handle under sterile laboratory conditions and avoid repeated freeze-thaw cycles.

Disclaimer:
This product is for laboratory research use only. It is not intended for human or animal consumption or for use in any diagnostic, therapeutic, or clinical applications.

Bronchogen's small size is hypothesized to allow direct cellular and nuclear penetration without receptor-mediated entry. In published research, AEDL is reported to interact with chromatin and DNA-regulatory regions, modulating expression of genes involved in bronchial epithelial cell proliferation, differentiation, and maintenance. Effects in lung tissue research models include modulation of inflammation markers and epithelial barrier components.

Bronchogen is studied in research on respiratory epithelial biology, lung-tissue aging, and bronchial cell function. It is a tissue-specific reference compound in the bioregulator peptide framework.